Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
TISI Team Inc
PRTK Paratek Pharmaceuticals Inc
KIRY Kiewit Royalty Trust
OCAXW OCA Acquisition Equity Warrant Exp 14 Jan 2026 *W EXP 01/31/2028
ABBV Abbvie Inc
IIIN Insteel Industries Inc
KO Coca-Cola Co
MOD Modine Manufacturing Co
WABC Westamerica Bancorp
Go

Health Care : Biotechnology |
Company profile

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Premarket

Last Trade
Delayed
$19.33
-0.25 (-1.28%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$19.58
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
10,143

10-day average volume:
22,513,671
10,143

Company Profile

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
170.06x
Price/Book (MRQ)
17.34x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2021
Current Month
228.3K
Previous Month
214.1K
Percent of Float
8.99%
Days to Cover
1.7676 Days

Share Information

LGVN is in a share class of common stock
Float
2.9M
Shares Outstanding
19.1M
Institutions Holding Shares
13
8.45%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

During the most recent quarter, 34K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.